文献速递主动脉疾病

STABLE II 试验:复合器械设计腔内治疗急性复杂性 B 型主动脉夹层

STABLE II clinical trial on endovascular treatment of acute, complicated type B aortic dissection with a composite device design.
PubMed 文献 · J Vasc Surg · 2019-08-30

STABLE II 为前瞻性、非随机、多中心研究,纳入 73 例急性复杂性 B 型主动脉夹层(伴破裂和/或分支血管灌注不良)患者,评估覆膜支架联合裸金属支架复合器械设计的安全性与有效性。30 天主要不良事件与生存率达标,1 年全因死亡 Kaplan-Meier 估计无死亡率为 80.3%±4.7%,假腔血栓形成率高,结果支持该器械用于破裂与灌注不良的治疗。

要点

  • 30 天死亡 5 例(6.8%),其中仅 1 例与手术相关。
  • 1 年全因死亡 Kaplan-Meier 无死亡率为 80.3%±4.7%。
  • 12 个月覆膜支架区假腔完全或部分血栓形成达 100%(46/46)。

核心结论

  • 30 天与 1 年结果显示,复合器械设计腔内治疗急性复杂性 TBAD 的破裂与灌注不良具有良好的临床与解剖学结局。
  • 5 年随访仍在进行中。

研究设计与样本

  • 前瞻性、非随机、多中心研究,2012 年 8 月至 2015 年 1 月在美国与日本机构纳入 73 例急性复杂性 TBAD 患者。
  • 患者 65.8% 为男性,平均年龄 60.7 岁,接受 Zenith Dissection Endovascular System 治疗。
  • 主要安全终点为 30 天无主要不良事件率,主要有效性终点为 30 天生存率;报告 30 天主要结局及至 1 年随访结果(数据截至 2018 年 3 月)。

主要发现

  • 73 例中 20 例(27%)伴主动脉破裂,57 例(78%)伴分支血管阻塞/受累,其中 4 例同时具备两种情况。
  • 覆膜支架在所有患者中使用(中位数 1,范围 1-3;64.4%(47/73)仅用 1 枚),裸金属夹层支架在 58/73 例(79.5%)中使用。
  • 30 天主要不良事件包括心肌梗死(1.4%)、肠缺血(1.4%)、需透析的肾功能不全/肾衰竭(6.8%)、卒中(6.8%)、截瘫或轻截瘫(5.5%)、延长通气支持(13.7%)。
  • 31 至 365 天发生 9 例死亡(仅 1 例与夹层修复相关);365 天内 9/73 例(12.3%)接受 10 次二次干预,无患者需转为开放手术。
  • 12 个月随访时覆膜支架区假腔完全或部分血栓形成为 100%(46/46),夹层支架区为 97.4%(38/39);最大经主动脉直径增长(>5 mm)在覆膜支架区为 14.9%(7/47),夹层支架区为 38.5%(15/39)。

临床怎么用

  • 对于急性复杂性 TBAD 伴破裂或分支血管灌注不良的患者,可考虑采用覆膜支架联合裸金属支架的复合器械设计行腔内治疗。
  • 术后 30 天内需重点监测心肌梗死、肠缺血、肾功能、卒中和脊髓缺血等主要不良事件。
  • 1 年内需关注二次干预风险及夹层支架段的主动脉直径增长,定期影像随访。

局限性

  • 研究为单臂、非随机设计,无对照组,样本量 73 例。
  • 随访报告至 1 年,长期(5 年)结果尚未获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and effectiveness of a composite device design (covered stent graft and bare metal stent) for the treatment of patients with acute, complicated type B aortic dissection (TBAD) presenting with aortic rupture and/or branch vessel malperfusion. METHODS: In this prospective, nonrandomized, multicenter study, 73 patients (65.8% male; mean age, 60.7 years) with acute, complicated TBAD were enrolled between August 2012 and January 2015 to receive treatment with the Zenith Dissection Endovascular System (William Cook Europe, Aps, Bjaeverskov, Denmark) at institutions in the United States and Japan. The primary safety end point was the rate of freedom from major adverse events at 30 days, and the primary effectiveness end point was the rate of survival at 30 days. This article reports primary outcomes at 30 days and follow-up results through 1 year, reflecting study data as of March 2018. RESULTS: Of 73 patients, 20 presented with aortic rupture (27%) and 57 presented with branch vessel obstruction/compromise (78%), including 4 patients presenting with both conditions. The covered stent graft was used in all patients (median, 1; range, 1-3; 1 stent graft used in 64.4%; 47/73), and the bare metal dissection stent was used in 58 of 73 patients (79.5%). Thirty-day mortality occurred in five patients (6.8%): one procedure related, three unrelated to dissection repair, and one indeterminate. Thirty-day major adverse events included myocardial infarction (1.4%), bowel ischemia (1.4%), renal insufficiency/renal failure requiring dialysis (6.8%), stroke (6.8%), paraplegia or paraparesis (5.5%), and prolonged ventilatory support (13.7%). Nine deaths occurred from 31 to 365 days (only one death related to dissection repair); the Kaplan-Meier estimate of freedom from all-cause mortality was 80.3% ± 4.7% at 1 year. Within 365 days, 9 of 73 patients (12.3%) underwent 10 secondary interventions; no patients required conversion to open surgery. At the 12-month follow-up, complete or partial thrombosis of the false lumen was seen in 100% of patients (46/46) within the stent graft region and in 97.4% of patients (38/39) within the dissection stent region. Growth (>5 mm) of the maximum transaortic diameter was observed in 14.9% of patients (7/47) in the stent graft region and in 38.5% of patients (15/39) within the dissection stent region at 12 months. CONCLUSIONS: Thirty-day and 1-year results from the STABLE II study demonstrated favorable clinical and anatomical outcomes for the treatment of rupture and malperfusion in the setting of acute, complicated TBAD. Five-year follow-up is ongoing.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lombardi JV, Gleason TG, Panneton JM, et al. STABLE II clinical trial on endovascular treatment of acute, complicated type B aortic dissection with a composite device design. J Vasc Surg. 2019. PMID: 31477479. doi:10.1016/j.jvs.2019.06.189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。